These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 37122538)

  • 21. Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal.
    Cohen KA; Abeel T; Manson McGuire A; Desjardins CA; Munsamy V; Shea TP; Walker BJ; Bantubani N; Almeida DV; Alvarado L; Chapman SB; Mvelase NR; Duffy EY; Fitzgerald MG; Govender P; Gujja S; Hamilton S; Howarth C; Larimer JD; Maharaj K; Pearson MD; Priest ME; Zeng Q; Padayatchi N; Grosset J; Young SK; Wortman J; Mlisana KP; O'Donnell MR; Birren BW; Bishai WR; Pym AS; Earl AM
    PLoS Med; 2015 Sep; 12(9):e1001880. PubMed ID: 26418737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing quality of life for multidrug-resistant and extensively drug-resistant tuberculosis patients.
    Vo NX; Xuan Doan TB; Kha Vo DN; Tran TK; Vo TQ
    J Pak Med Assoc; 2019 Jun; 69(Suppl 2)(6):S137-S157. PubMed ID: 31369544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis.
    Dheda K; Chang KC; Guglielmetti L; Furin J; Schaaf HS; Chesov D; Esmail A; Lange C
    Clin Microbiol Infect; 2017 Mar; 23(3):131-140. PubMed ID: 27756712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Opportunities and challenges of using five-membered ring compounds as promising antitubercular agents.
    Yan M; Xu L; Wang Y; Wan J; Liu T; Liu W; Wan Y; Zhang B; Wang R; Li Q
    Drug Dev Res; 2020 Jun; 81(4):402-418. PubMed ID: 31904877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibiotic resistance acquisition versus primary transmission in the presentation of extensively drug-resistant tuberculosis.
    O'Toole RF
    Int J Mycobacteriol; 2022; 11(4):343-348. PubMed ID: 36510916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tuberculosis: An Overview of the Immunogenic Response, Disease Progression, and Medicinal Chemistry Efforts in the Last Decade toward the Development of Potential Drugs for Extensively Drug-Resistant Tuberculosis Strains.
    Sharma A; De Rosa M; Singla N; Singh G; Barnwal RP; Pandey A
    J Med Chem; 2021 Apr; 64(8):4359-4395. PubMed ID: 33826327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug discovery in tuberculosis. New drug targets and antimycobacterial agents.
    Campaniço A; Moreira R; Lopes F
    Eur J Med Chem; 2018 Apr; 150():525-545. PubMed ID: 29549838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects.
    Yew WW
    Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.
    Lange C; Abubakar I; Alffenaar JW; Bothamley G; Caminero JA; Carvalho AC; Chang KC; Codecasa L; Correia A; Crudu V; Davies P; Dedicoat M; Drobniewski F; Duarte R; Ehlers C; Erkens C; Goletti D; Günther G; Ibraim E; Kampmann B; Kuksa L; de Lange W; van Leth F; van Lunzen J; Matteelli A; Menzies D; Monedero I; Richter E; Rüsch-Gerdes S; Sandgren A; Scardigli A; Skrahina A; Tortoli E; Volchenkov G; Wagner D; van der Werf MJ; Williams B; Yew WW; Zellweger JP; Cirillo DM;
    Eur Respir J; 2014 Jul; 44(1):23-63. PubMed ID: 24659544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multidrug and extensively drug-resistant tuberculosis.
    Maitre T; Aubry A; Jarlier V; Robert J; Veziris N;
    Med Mal Infect; 2017 Feb; 47(1):3-10. PubMed ID: 27637852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imidazo[1,2-A]Pyridine: Potent Biological Activity, SAR and Docking In-vestigations (2017-2022).
    Narayan A; Patel S; B Baile S; Jain S; Sharma S
    Infect Disord Drug Targets; 2024 Mar; ():. PubMed ID: 38509674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advancement of Imidazo[1,2-
    Moraski GC; Markley LD; Cramer J; Hipskind PA; Boshoff H; Bailey M; Alling T; Ollinger J; Parish T; Miller MJ
    ACS Med Chem Lett; 2013 Jul; 4(7):675-679. PubMed ID: 23930153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extensively and pre-extensively drug resistant tuberculosis in clinical isolates of multi-drug resistant tuberculosis using classical second line drugs (levofloxacin and amikacin).
    Mirza IA; Khan FA; Khan KA; Satti L; Ghafoor T; Fayyaz M
    J Coll Physicians Surg Pak; 2015 May; 25(5):337-41. PubMed ID: 26008658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic, phenotypic and demographic characterization of
    Losev Y; Rubinstein M; Nissan I; Haviv P; Barsky Y; Volinsky M; Bar-Giora G; Zouher T; Hamawi M; Valenci GZ; Kutikov I; Shwartz HK; Dveyrin Z; Chemtob D; Rorman E
    Front Cell Infect Microbiol; 2023; 13():1196904. PubMed ID: 37928179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coumarin hybrid derivatives as promising leads to treat tuberculosis: Recent developments and critical aspects of structural design to exhibit anti-tubercular activity.
    Reddy DS; Kongot M; Kumar A
    Tuberculosis (Edinb); 2021 Mar; 127():102050. PubMed ID: 33540334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
    Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C
    Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistant TB: Newer Drugs and Community Approach.
    Gothi D; Joshi JM
    Recent Pat Antiinfect Drug Discov; 2011 Jan; 6(1):27-37. PubMed ID: 21192779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.